RESUMO
Background: Little is known about the extent of alignment between hematopoietic stem cell transplant (HSCT) patients and their healthcare proxies with respect to advance care planning (ACP). Aim: To determine if a structured three-step process using the letter advance directive (LAD) could (1) allow for the differences in opinion between patient-proxy dyads to surface and (2) help bridge preexisting discordance about specific treatment choices. Design: Blinded to each other, the HSCT patient (LAD-1) and proxy (LAD-2) each completed the LAD (step 1). They unmasked, compared LAD-1 and LAD-2, and discussed their choices (step 2). They completed a final letter directive (LAD-3) by consensus (step 3). Settings/Participants: Convenience sample of eighty dyads (patient and proxy) at a regional HSCT referral center. Results: The mean patient-proxy concordance was 72.9% for the 12 questions in the LAD. Wanting to be pain free at the end of life was the statement with the most amount of agreement (88.75% in LAD-1, 91.25% in LAD-2, and 90% in LAD-3). Patient-proxy dyads had notable discordance related to specific treatments. The highest discordance was related to ventilator support (46.3% of patients refused it, while 58.8% of proxies refused on behalf of the patient). Overall, proxies were more likely than patients to opt in for dialyses and hospice care but more likely to opt out for cardiac resuscitation and sedation to palliate refractory symptoms. On open discussion, patient-proxy discordance mostly resolved in favor of the patient. Conclusions: The ACP process should allow for patient-proxy differences to surface, facilitate a discussion about the granular details with the goal of reaching consensus. Our three-step approach using the LAD is an effective way to identify areas of patient-proxy concordance and discordance about specific treatment preferences. A structured patient-proxy discussion using the LAD helped reconcile discordance and most often in favor of a patient's original wishes.
Assuntos
Planejamento Antecipado de Cuidados , Diretivas Antecipadas , Correspondência como Assunto , Procurador , Adulto , Idoso , Idoso de 80 Anos ou mais , Tomada de Decisões , Feminino , Transplante de Células-Tronco Hematopoéticas , Humanos , Masculino , Pessoa de Meia-Idade , Assistência Terminal , Condicionamento Pré-Transplante , Adulto JovemRESUMO
The purpose of this cross-sectional descriptive study is to define sexual dysfunction and menopausal symptoms in women following cytotoxic or immunosuppressive medication for the treatment of malignant or life-threatening hematolymphoid diseases. These women were preparing to undergo hematopoietic cell transplantation (HCT) as the next step in their treatment plan. It is assumed that sexual dysfunction and symptoms of premature menopause are more pronounced post-HCT due to the intensity of the preparative regimen on the hypothalamic-pituitary-gonadal axis. This study included 48 pre-menopausal women and 28 spouses/partners. Data were collected using five self-report instruments (demographic and medical, the Female Sexual Function Index, the Menopause-specific Quality of Life, the Psychosocial Adaptation to Illness Scale, and a global quality of life score). The main research variables were female sexual functioning, symptoms of menopause, and quality of life. The findings indicate that 73% of women report decreased libido and 48% report dissatisfaction with their overall sex life. Hot flashes, the most common symptom of menopause are reported by 46% and 27% report the hot flashes moderate to severe in intensity. Vaginal dryness was reported by 35% with 23% reporting the vaginal dryness to be moderate to severe. The mean quality of life (QOL) score in women was 69+/-25 with a range of 2-100 (on a scale of 0-100 with 100 being an excellent QOL). The findings indicate that women treated with standard dose chemotherapy and immunosuppressive therapy for malignant and life-threatening hematolymphoid diseases experience alterations in sexual health and symptoms of premature menopause. The results show that the desire, arousal, and orgasm phase of the sexual response cycle are altered. Additionally, nearly half of the women are experiencing hot flashes, the most common symptom of menopause and over a third report vaginal dryness. There are statistically significant correlations between altered sexual health, menopausal symptoms, and QOL scores.
Assuntos
Atitude Frente a Saúde , Transplante de Células-Tronco Hematopoéticas , Qualidade de Vida/psicologia , Comportamento Sexual/psicologia , Saúde da Mulher , Adaptação Psicológica , Adulto , Antineoplásicos/efeitos adversos , Estudos Transversais , Feminino , Neoplasias Hematológicas/psicologia , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Transplante de Células-Tronco Hematopoéticas/psicologia , Humanos , Imunossupressores/efeitos adversos , Menopausa Precoce/efeitos dos fármacos , Menopausa Precoce/psicologia , Pessoa de Meia-Idade , Pesquisa Metodológica em Enfermagem , Satisfação Pessoal , Comportamento Sexual/efeitos dos fármacos , Disfunções Sexuais Fisiológicas/etiologia , Disfunções Sexuais Psicogênicas/etiologia , Cônjuges/psicologia , Inquéritos e Questionários , Condicionamento Pré-Transplante/efeitos adversos , Condicionamento Pré-Transplante/psicologiaRESUMO
PURPOSE: This article provides an overview of the currently available treatments for type 2 diabetes (T2D), outlining the most up to date information to assist nurse practitioners (NPs) to make informed prescribing decisions for T2D therapy once patients are no longer able to maintain blood glucose control using lifestyle modification and/or metformin therapy. DATA SOURCES: Published guidelines for the management of T2D, review articles, primary manuscripts, and FDA prescribing information documents. CONCLUSIONS: In the past, options for the treatment of T2D were limited. However, there is now an ever increasing number of available therapeutic choices for T2D, that, as well as glycemic control, offer significant additional benefits, particularly in terms of reducing hypoglycemic risk and weight gain. Consequently, these newer agents provide both patients and NPs with a much greater choice for ongoing therapy. IMPLICATIONS FOR PRACTICE: The differing benefits and risk profiles shown by the currently available antidiabetic treatments provide NPs with a unique opportunity to tailor treatment plans more closely to the requirements of each patient. This approach can ensure that the right drug reaches the right patient, which should in turn promote greater treatment compliance and improved outcomes, ultimately slowing disease progression.